Skip to main content

Table 1 Clinical characteristics of the population and comparison of the patients with P. aeruginosa (P. a) without mutation vs with mutation

From: Risk factors and the resistance mechanisms involved in Pseudomonas aeruginosa mutation in critically ill patients

  Overall population No mutation
n= 119
Mutation
n=34
p
Median 95% CI Median 95% CI Median 95% CI
Age (years) 64 62 - 66 65 63 - 67 61 56 - 65 0.189
SAPS II 58 55 - 63 58 56 - 63 51 41 - 67 0.356
Length of stay (days) 21 18 - 25 18 16 - 23 34 26 - 40 0.0002*
Duration of ventilation (days) 16 14 - 20.6 14.5 13 - 17 31.5 25 - 35 0.0001*
Prior hospitalization period 6 4 - 8 5 3 - 8 9 5 - 18 0.094
Colonization period 9 7 - 11 9 7 - 11 9.5 3 - 15 0.981
Infection period 10.5 7 - 13 10.5 6 - 13 10.5 2 - 15.8 0.625
Duration 1st treatment P.a 1(n: 68/30) 4 4 - 5 4.0 3 – 5.6 4.5 3 – 6 0.656
Duration 2nd treatment P.a 2(n: 41/26) 6 5 - 9 5.0 3 – 7 8.5 5.6 - 12 0.041*
Duration 3rd treatment P.a (n: 13/15) 8 2 – 10.6 6.0 1.5 – 11 9.0 2.5 - 13 0.579
Number of ATB before P. aeruginosa in ICU 2 1 - 2 2 1 - 2 2 1 - 2 0.598
Gender M/F   94 (79%)/25 (21%) 22 (64.7%)/12 (35.3%) 0.112
Clinical recovery no/yes 50(32.7%)/103(67.3%) 34 (28.6%) / 85 (71.4%) 16 (47.1%)/18 (52.9%) 0.061
Bacteriological recovery no/yes 121(79.1%)/32(20.9%) 89 (74.8%) / 30 (25.2%) 32 (94.1%) / 2 (5.9%) 0.016*
Death no/yes 101 (66%)/52 (34%) 79 (66.4%) / 40 (33.6%) 22 (64.7%) / 12 (35.3%) 0.840
Reason for hospitalization
 Multiple trauma 7 (4.6%) 7 (5.9%) 0 (0 %) 0.351
 Medical 75 (49%) 58 (48.7%) 17 (50 %)
 Surgical 71 (46.4%) 54 (45.4%) 17 (50%)
Sampling type
 Tracheal aspiration   77 (64.7%) 21 (61.8%) 0,698
 Bronchoalveolar lavage   18 (15.1%) 6 (17.6%)
 Blood cultures   17 (14.3%) 5 (14.7%)
 Intraperitoneal sample   3 (2.5%) 2 (5.9%)
Prior hospitalization no/yes 41 (26.8%)/112(73.2%) 33 (27.7%) / 86 (72.3%) 8 (23.5%) / 26 (76.5%) 0.826
  1. * signify that it is considered to be statistically significant with p < 0.05